TScan Therapeutics $100 million IPO
Davis Polk advised the underwriters in connection with the initial public offering of 6,666,667 shares of common stock of TScan Therapeutics, Inc. at $15.00 per share, for total gross proceeds of $100 million. TScan’s common stock is listed on the Nasdaq Global Market under the symbol “TCRX.”
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
The Davis Polk corporate team included partners Marcel Fausten and Richard D. Truesdell Jr. and associates Clare Conroy and Xi (Brooke) Zheng. Counsel Kiara L. Rankin and associate Shay Moyal provided tax advice. Partner David R. Bauer and associates S. Dream Montgomery and Marisa Elena Bannon provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.